Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lexapro Prescribers: Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
July 28, 2008
Pharmacogenetic Tests for Antidepressants Disappointing So Far
Analysis of: TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy | www.medicalnewstoday.com
Author: GLG Expert Contributor
-Pharmacogenetic tests have not made it into the treatment or assessment process for most physicians. -Until the cost for these tests become negligible -- or, included in the cost of a particular antidepressant -- psychopharmacogenetic testing will not make it into the mainstream. 
May 27, 2008
Head to Head Comparisons will Help Patients but Hurt Profits
Analysis of: Warning over drug trial’s effects on testing | www.ft.com
Author: GLG Expert Contributor
Direct comparisons between potential competing agents often do not exist Initial FDA approval is usually based on comparisons to placebo A new approval does necessarily mean that the new agent is better than existing ones, although this is implied by industry Industry bears all the costs of efficacy...
May 19, 2008
Bigger markets or validation of current use?
Analysis of: FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder | www.astrazeneca.com
Author: GLG Expert Contributor
Specific pharmacology Borad range of indications Validation of some current prescribing patterns Possible gradual increased use of the medication
May 14, 2008
Abbot's potentially interesting avenue of approach to adult ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
This is a potentially interesting alternative to current ADHD stimulant treatment. There is, I believe, existing literature on the efficacy of nicotine patches in the treatment of severe,otherwise intractable ADHD in children, which would seem to support these results. Of course, much work remains to...
May 14, 2008
Tapentadol: The New Ultram?
Analysis of: Johnson & Johnson Presents Tapentadol Phase 3 Clinical Data at American Pain Society's Annual Meeting | www.investor.jnj.com
Author: GLG Expert Contributor
Don't bother listening to the May 6 audio presentation, as it is a useless waste of time.  Just look at the pdf slide presentation, showing tapentadol IR to provide equivalent pain control to 10 or 15mg oxycodone, with reduced GI side effects, in treating acute bunionectomy pain and also arthritis...
May 12, 2008
Neuronal nicotinic receptor agonists potential breakthrough for ADHD research
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
1. Effective treatment for ADHD 2. Well tolerated with few side effects 3. Help with smoking, a big problem in ADHD patients important 4. Advantage in not being Schedule II may be helpful
May 12, 2008
Important New Data for Children and Adolescents
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial
May 12, 2008
NNRs: A Novel direction?
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
A novel neurochemical approach. Modulation of key neurotransmitter systems. Implications for a wide variety of psychiatric disorders.
April 30, 2008
FDA Gives ISIS (Nasdaq: ISIS) a Gift (?) in its Efforts to Develop Mipomersen
Analysis of: FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen | online.wsj.com
Author: GLG Expert Contributor
Sometimes what appears to be an obstacle in the path to drug development has the opposite effect.  In the case of the FDA's response to Mipomersen this may well be the case...and it may be the harbinger of a more "collaborative" approach by the FDA.
April 30, 2008
Alynlam (Nasdaq: ALNY) Brings the RNA Messenger to the Messenger RNA
Analysis of: Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids', a Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics | www.businesswire.com
Author: GLG Expert Contributor
Alnylam (Nasdaq: ALNY) has hit upon a novel concept (in collaboration with MIT) in enabling RNAi therapeutics to reach their intended targets.  Look for an explosion of applications.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 158

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-28T21:45:18.233